Last reviewed · How we verify
Oxytocin only
At a glance
| Generic name | Oxytocin only |
|---|---|
| Sponsor | Darlington-Peter Chibuzor Ugoji |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Intra-Umbilical Vein Oxytocin Injection as an Adjunct to Active Management of the Third Stage of Labour (NA)
- Efficacy of Intravenous Oxytocin to Speed Recovery After THA (PHASE2)
- Differences in Mechanistic Measures (Oxytocin and Cortisol) of Therapeutic Alliance Between A Talk-Based Therapy and Soft-Tissue Mobilization in Individuals With Chronic Spinal Pain (NA)
- PGE2 Followed by Oxytocin vs Oxytocin in Term PROM (POXY-PROM) (NA)
- Comparison of the Effect of Carbetocin Versus Oxytocin in the Prevention of Postpartum Hemorrhage After Emergency Caesarean Section in Antenatal Low-risk Patients (NA)
- Umbilical Cord Drainage to Prevent Postpartum Hemorrhage (NA)
- Open, Randomized Feasibility Trial on the Safety and Performance of the INGA Catheter for Labor Induction (NA)
- Carbetocin Uterotonic Treatment in Twin Pregnancies for Prevention of Postpartum Hemorrhage (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oxytocin only CI brief — competitive landscape report
- Oxytocin only updates RSS · CI watch RSS
- Darlington-Peter Chibuzor Ugoji portfolio CI